Caplin Point Laboratories Ltd
NSE:CAPLIPOINT
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 198
2 121.7
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Caplin Point Laboratories Ltd
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
| Market Cap | EV/EBITDA | ||||
|---|---|---|---|---|---|
| IN |
|
Caplin Point Laboratories Ltd
NSE:CAPLIPOINT
|
159.1B INR | 24.9 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -5 459 134.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
749.7B USD | 48.1 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 3 846.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
3.4T DKK | 24.6 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
372B USD | 12.2 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
257.3B USD | 10.7 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
200.4B CHF | 9.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
162.7B GBP | 169.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
179.9B CHF | 10 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
146B USD | 234.4 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.
You don't have any saved screeners yet
